Duopharma Biotech

DPHARMA

MYL7148OO009

Pharmaceuticals

End-of-day quote BURSA MALAYSIA Other stock markets 18:00:00 2024-05-30 EDT			5-day change	1st Jan Change
1.2 ^MYR	-1.64%		-2.44%	-4.76%

05-24	Duopharma’s Attributable Income Shrinks in Q1; Shares Down 2%	MT
05-23	Duopharma Biotech Berhad Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Duopharma Biotech Berhad Appoints Nik Moustpha Bin Haji Nik Hassan as Independent and Non Executive Member of Audit Committee

August 17, 2021 at 08:47 am

Duopharma Biotech Berhad announced appointment of Nik Moustpha Bin Haji Nik Hassan as Independent and Non Executive Member of Audit Committee with effect from August 17, 2021.

Latest news about Duopharma Biotech

Duopharma’s Attributable Income Shrinks in Q1; Shares Down 2%	05-24	MT
Duopharma Biotech Berhad Reports Earnings Results for the First Quarter Ended March 31, 2024	05-23	CI
Duopharma Biotech Clinches MYR578 million Supply Deals	05-01	MT
Duopharma Biotech Berhad Announces the Appointment of Mohd Haris Bin Mohd Arshad as Non Independent and Non Executive Member of Nomination and Remuneration Committee	03-20	CI
Duopharma Biotech Berhad Appoints Mohd Haris Bin Mohd Arshad as Non-Independent and Non-Executive Director	03-20	CI
Duopharma Biotech Berhad Announces the Resignation of Amizar Binti Mizuar as Non Independent and Non Executive Member of Nomination and Remuneration Committee	03-20	CI
Duopharma Biotech Berhad Announces the Resignation of Puan Amizar Binti Mizuar as Non Independent and Non Executive Director	03-20	CI
Duopharma Biotech Berhad Announces the Cessation of Encik Muhammad Shukri Bin Ismail as Non Independent and Non Executive Alternate Director	03-20	CI
Duopharma Biotech's Profit Plummets in Q4 2023	02-23	MT
Duopharma Biotech Berhad Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-22	CI
Duopharma Biotech Berhad Announces Second Interim Dividend in Respect of the Financial Year Ended 31 December 2023, Payable on 21 March 2024	02-22	CI
Duopharma Biotech Issues Further Islamic Debt Worth MYR29 Million	12-18	MT
Duopharma Biotech Berhad Makes a Further Sukuk Wakalah Issuance of RMB 29.0 Million Under the Sukuk Wakalah Programme	12-15	CI
Duopharma Biotech's Profit Drops in Q3	11-09	MT
Duopharma Biotech Berhad Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-08	CI
Duopharma Biotech Bags Supply Deal Extension from Pharmaniga	23-10-25	MT
Duopharma Biotech Berhad Declares Interim Dividend for the 30 June 2023, Payable on 22 September 2023	23-08-24	CI
Duopharma Biotech Berhad Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24	CI
Duopharma Biotech Berhad Appoints ENCIK MUHAMMAD SHUKRI BIN ISMAIL as Non Independent and Non Executive Alternate Director	23-08-01	CI
The Live Green Company announced that it expects to receive $1 million in funding from Duopharma Biotech Berhad	23-07-31	CI
Duopharma Biotech Berhad Appoints Datin Paduka Kartini Binti Hj Abdul Manaf as Independent and Non-Executive Member of Risk Committee, Date of Change 1 June 2023	23-05-31	CI
Duopharma Biotech Berhad Announces Re-Designation of Dato' Eisah Binti A. Rahman, Member of Nomination and Remuneration Committee as Independent and Non-Executive Chairman of Nomination and Remuneration Committee, Date of Change 1 June 2023	23-05-31	CI
Duopharma Biotech Berhad Appoints Dato' Dr. Zaki Morad Bin Mohamad Zaher as Independent and Non-Executive Member of Nomination and Remuneration Committee, Date of Change 1 June 2023	23-05-31	CI
Duopharma Biotech Berhad Appoints Datin Paduka Kartini Binti Hj Abdul Manaf as Independent and Non-Executive Director, Date of Change 1 June 2023	23-05-31	CI
Duopharma Biotech Berhad Announces Re-Designation of Dato' Eisah Binti A. Rahman from Independent Non-Executive Director to Senior Independent Non-Executive Director, Date of Change 1 June 2023	23-05-31	CI

Duopharma Biotech Berhad is a Malaysia-based pharmaceutical company. The Company is engaged in the manufacturing and distribution of pharmaceutical products. Its business segments include Consumer Healthcare (CHC), Ethical Classic Business (ECB) and Ethical Specialty Business (ESB). The CHC is engaged in the manufacturing, marketing and distribution of over-the-counter products, such as vitamins and supplements, analgesics, eyecare and antacids to the domestic, regional and international markets. Its CHC brands include Flavettes, CHAMPS, Uphamol and Eye Glo. The ECB comprises more than 300 generic drugs manufactured by the Company, such as Crystorvas, Prelica and Omesec, among others. The ESB is focused on drugs for targeted conditions, as well as medical devices and consumables. It has also diversified into the biosimilars space with technology and commercialization collaborations with international partners. ERYSAA, Basalog One and Zuhera are a few commercialized biosimilar brands.

Sector

Pharmaceuticals

Calendar

2024-06-05 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Duopharma Biotech

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.2 MYR

Average target price

1.448 MYR

Spread / Average Target

+20.63%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
DUOPHARMA BIOTECH	-4.76%	245M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+15.91%	41.97B
OTSUKA HOLDINGS CO., LTD.	+22.40%	22.34B
SANDOZ GROUP AG	+18.48%	15.25B
CIPLA LIMITED	+16.12%	14B
ZYDUS LIFESCIENCES LIMITED	+45.12%	12.06B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-9.58%	6.8B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+14.18%	5.49B

Generic Pharmaceuticals